EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLD

Salvatore Petta iD, Angelo Armandi iD, Elisabetta Bugianesi

Liver International · 2025-03 · 45 (3)

DOI: 10.1111/liv.16133 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Liver International, online erschienen am 16.10.2024. Verfasst von Salvatore Petta und 2 weiteren Autor:innen. Beteiligte Einrichtung: Sezione di Gastroenterologia, Di.Bi.M.I.S, University of Palermo, Palermo, Italy. Hauptthemen laut MEDLINE: Lipase, Membrane Proteins, Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PNRR-MAD-2022-12375656, PRIN 2022 2022L273C9, RF-2021-12372399.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a heterogenous clinical and histopathological entity, where multiple metabolic co‐factors are intertwined with high interindividual variability. The impact and severity of each factor (including obesity and type 2 diabetes) define a systemic dysmetabolism that can lead to either advanced liver disease and its complication (including hepatocellular carcinoma and clinical events related to portal hypertension) or extrahepatic events: incident cardiovascular disease, chronic kidney disease and extrahepatic cancers. The balance between environmental factors and genetic susceptibility has unique implications in MASLD: the intermittent injury of metabolic co‐factors, their fluctuation over time and their specific management, are counterbalanced by the presence of gene variants that can significantly impact the disease at multiple levels. The I148M variant in the PNPLA3 gene is the most investigated genetic susceptibility that induces a more severe steatohepatitis, enhanced fibrogenesis and can shape the incidence of long‐term clinical events regardless of, or worsened by, other metabolic risk factors. Methods and Results In this review, we will summarise the updated evidence on the natural history of MASLD accounting for classical metabolic risk factors, the role of PNPLA3 in clinical sub‐phenotyping (e.g., ‘lean MASLD’), impact on disease severity and fibrosis progression, as well as its role for prognostication, alone or in combination with non‐invasive tools into polygenic risk scores.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LipaseMembrane ProteinsFatty LiverNon-alcoholic Fatty Liver DiseaseHumansGenetic Predisposition to DiseaseRisk FactorsDisease ProgressionAcyltransferasesPhospholipases A2, Calcium-Independent

Stichwörter der Autor:innen

PNPLA3cardiovascular diseasehepatocellular carcinomaliver fibrosismetabolic dysfunction‐associated Steatotic liver diseasemetabolic syndromeportal hypertensionsingle nucleotide polymorphisms

Substanzen

LipasePNPLA3 protein, humanMembrane ProteinsAcyltransferasesPhospholipases A2, Calcium-Independent

Autor:innen und Institutionen

  • Sezione di Gastroenterologia, Di.Bi.M.I.S, University of Palermo, Palermo, Italy.
  • Division of Gastroenterology and Hepatology, Department of Medical Sciences, University of Turin, Turin, Italy.

ORCID-Profile: Salvatore Petta, Angelo Armandi

Förderung

  • PNRR-MAD-2022-12375656
  • PRIN 2022 2022L273C9
  • RF-2021-12372399
  • PNRR "D3 4 Health - Digital Driven Diagnostics, prognostics and therapeutics for sustainable Health care"
  • PNRR M4C2I1.3

Zitieren

APA

Petta, S., Armandi, A., & Bugianesi, E. (2025). Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLD. Liver International, 45(3). https://doi.org/10.1111/liv.16133

Vancouver

Petta S, Armandi A, Bugianesi E. Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLD. Liver International. 2025;45(3). doi:10.1111/liv.16133

BibTeX
@article{Petta2025,
  author = {Petta, Salvatore and Armandi, Angelo and Bugianesi, Elisabetta},
  title = {Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLD},
  journal = {Liver International},
  year = {2025},
  volume = {45},
  number = {3},
  doi = {10.1111/liv.16133}
}
Kostenlos starten →